CRISPR Therapeutics AG, headquartered in Zug, develops gene-based medicines for serious diseases using its CRISPR/Cas9 platform and went public on October 19, 2016. The company focuses on gene editing to treat genetically-defined diseases and enhance cellular therapies.
CRISPR Therapeutics AG (CRSP) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, CRISPR Therapeutics AG's actual EPS was -$1.58, missing the estimate of -$1.28 per share, resulting in a -23.86% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
